<?xml version="1.0" encoding="UTF-8"?>
<p id="Par49">However, in addition to addressing the purely scientific aspects, success in drug development also depends on funding opportunities for late preclinical development phases which are significantly more expensive than early-stage discovery. Experience shows that promising ideas have often failed in this “Valley of Death” (a term coined by former NIH director, Elias Zerhouni) [
 <xref ref-type="bibr" rid="CR93">93</xref>]. Feasible regulatory frameworks and efficient data-sharing ecosystems [
 <xref ref-type="bibr" rid="CR94">94</xref>] that also ensure ethical leadership and governance [
 <xref ref-type="bibr" rid="CR95">95</xref>] as well as new funding instruments (for example, similar to the recently initated public-private partnership set up to boost research and drug development in infectious diseases and thereby to address market failures [
 <xref ref-type="bibr" rid="CR84">84</xref>]) will facilitate drug development.
</p>
